Survival outcomes following neoadjuvant therapy for resectable cholangiocarcinoma: a systematic review and reconstructed individual patient data meta-analysis
In brief
About 7 in 10 patients with resectable biliary cancer reached curative-intent surgery
Across six prospective trials, 71% of patients receiving preoperative treatment underwent curative-intent surgery; 51% were alive at three years. The findings suggest this approach is feasible for selected patients, but a substantial share did not reach curative surgery. Without randomized comparisons against current surgery-first care, its role in routine treatment remains uncertain.
- Journal
- Cancer treatment reviews (Q1)
- Published
- 13 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Giovanni Trovato, Laura Chiofalo, Cinzia Bagalà, Francesca Belenghi, Kristian Shtembari, Daniele Lavacchi, et al.
- PMID
- 43044180
- DOI
- 10.1016/j.ctrv.2026.103243
Why clinicians should know about it
- Picked for Surgery (top studies of the week, 22 November 2026): Neoadjuvant therapy and resection outcomes in cholangiocarcinoma
Abstract
BACKGROUND: The role of neoadjuvant systemic therapy in resectable biliary tract cancer (BTC) remains uncertain. We conducted a systematic review and meta-analysis to assess the feasibility, surgical outcomes, radiological activity, and survival associated with neoadjuvant treatment. METHODS: PubMed/MEDLINE, Embase, and CENTRAL were searched through April 30, 2026 for prospective phase II-III trials evaluating neoadjuvant systemic therapy followed by surgery in resectable BTC. Binary outcomes were pooled using random-effects models. Individual patient data were reconstructed from published Kaplan-Meier curves, and landmark survival estimates were synthesized using random-effects meta-analysis. RESULTS: Six prospective trials comprising seven active neoadjuvant treatment arms were included. Pooled neoadjuvant-to-surgery completion and curative-intent resection rates were 79.0% (95% CI, 63.0-89.0) and 71.0% (95% CI, 54.0-84.0), respectively. The pooled objective response rate was 21.2% (95% CI, 9.0-42.3), and the intention-to-treat R0 resection rate was 63.6% (95% CI, 44.7-79.0). Pooled overall survival was 84.0% (95% CI, 78.0-89.0), 63.0% (55.0-71.0), and 51.0% (44.0-59.0) at 12, 24, and 36 months, respectively. Corresponding recurrence-related survival estimates were 60.0% (51.0-69.0), 41.0% (33.0-50.0), and 37.0% (30.0-45.0). Findings were consistent across sensitivity analyses. CONCLUSION: Neoadjuvant systemic therapy is feasible in selected patients with resectable BTC, although a substantial proportion do not ultimately undergo curative surgery. Emerging prospective evidence supports further evaluation of perioperative strategies, particularly in high-risk disease, but randomized trials against contemporary surgery-first approaches are required before routine adoption.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.